{"id":"https://openalex.org/W7096423039","doi":null,"title":"Group and the Diabetes and Cancer Research Consortium","display_name":"Group and the Diabetes and Cancer Research Consortium","alternate_titles":[],"publication_year":null,"publication_date":null,"ids":{"openalex":"https://openalex.org/W7096423039"},"language":"en","primary_location":{"id":"pmh:oai:CiteSeerX.psu:10.1.1.867.9074","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.867.9074","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.bladderandbowelfoundation.org/wp-content/uploads/2014/12/Levin-et-al-Pioglitazone-and-bladder-cancer-risk.pdf","raw_type":"text"},"parent_works":[],"lineage":["https://openalex.org/W7096423039"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"D. Levin :h. M. Colhoun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Levin :h. M. Colhoun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"R. Sund","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Sund","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"J. Tuomilehto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Tuomilehto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"S. A. Hartikainen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. A. Hartikainen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"J. Tuomilehto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Tuomilehto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.7465999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.7465999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.11969999969005585,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.016300000250339508,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":1.0},{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.972000002861023},{"id":"https://openalex.org/keywords/allocation-bias","display_name":"allocation bias","score":0.7900000214576721},{"id":"https://openalex.org/keywords/cumulative-drug-exposure","display_name":"cumulative drug exposure","score":0.7490000128746033},{"id":"https://openalex.org/keywords/time-dependent-analysis","display_name":"time-dependent analysis","score":0.6790000200271606},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4740000069141388},{"id":"https://openalex.org/keywords/cancer-risk","display_name":"cancer risk","score":0.4309999942779541}],"concepts":[{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.9718000292778015},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7764000296592712},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.6629999876022339},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5752999782562256},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5478000044822693},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49050000309944153},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47690001130104065},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.37689998745918274},{"id":"https://openalex.org/C2779318504","wikidata":"https://www.wikidata.org/wiki/Q1438035","display_name":"Research design","level":2,"score":0.3046000003814697},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.28290000557899475},{"id":"https://openalex.org/C3020493868","wikidata":"https://www.wikidata.org/wiki/Q55631277","display_name":"Real world data","level":2,"score":0.28200000524520874},{"id":"https://openalex.org/C3020167199","wikidata":"https://www.wikidata.org/wiki/Q5031455","display_name":"Cancer survival","level":3,"score":0.27489998936653137},{"id":"https://openalex.org/C2781311116","wikidata":"https://www.wikidata.org/wiki/Q83306","display_name":"Group (periodic table)","level":2,"score":0.26499998569488525},{"id":"https://openalex.org/C2778527826","wikidata":"https://www.wikidata.org/wiki/Q1787017","display_name":"Cancer registry","level":3,"score":0.26249998807907104}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:CiteSeerX.psu:10.1.1.867.9074","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.867.9074","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.bladderandbowelfoundation.org/wp-content/uploads/2014/12/Levin-et-al-Pioglitazone-and-bladder-cancer-risk.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2069723602","https://openalex.org/W2899412681","https://openalex.org/W2507604320","https://openalex.org/W2109091082","https://openalex.org/W1855672666","https://openalex.org/W2284212734","https://openalex.org/W2157761919","https://openalex.org/W2325092926","https://openalex.org/W1991441696","https://openalex.org/W2543390429"],"abstract_inverted_index":{"Aims/hypothesis":[0],"The":[1,21,43],"evidence":[2],"on":[3,35,52],"the":[4,29,53,59,84],"association":[5],"between":[6],"pioglitazone":[7,34,57],"use":[8],"and":[9,69],"bladder":[10,36],"cancer":[11,37,68],"is":[12],"contradictory,":[13],"with":[14,74],"many":[15],"studies":[16],"subject":[17],"to":[18,27,33],"allocation":[19,46],"bias.":[20],"aim":[22],"of":[23,31,56],"our":[24],"study":[25],"was":[26,48],"examine":[28],"effect":[30,55],"exposure":[32],"risk":[38],"internationally":[39],"across":[40,83],"several":[41],"cohorts.":[42],"potential":[44],"for":[45],"bias":[47],"minimised":[49],"by":[50],"focusing":[51],"cumulative":[54],"as":[58],"primary":[60],"end-point":[61],"using":[62],"a":[63],"time-dependent":[64],"approach.":[65],"Methods":[66],"Prescription,":[67],"mortality":[70],"data":[71],"from":[72,80],"people":[73],"type":[75],"2":[76],"diabetes":[77],"were":[78],"obtained":[79],"six":[81],"populations":[82],"world":[85],"(British":[86],"Columbia,":[87]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7096423039","counts_by_year":[],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2025-10-27T00:00:00"}
